Source: PR Newswire

Phanes: Phanes Therapeutics' PT886 granted Fast Track designation for the treatment of patients with metastatic claudin 18.2-positive pancreatic adenocarcinoma by the FDA

/PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology,...

Read full article »

Phanes's Competitors | Phanes's News | Phanes's Financials

Followers on Owler

Est. Annual Revenue

$100K-5.0M

Est. Employees

1-25

Founder & CEO

Ming Wang

CEO Approval Rating

90/100

Phanes is a California-based biotechnology company that provides drug discovery, development and related services for the treatment of cancer and opthalmic diseases.